Arvinas LLC, announced that it has appointed Dr. John Houston as President of Research and Development and Chief Scientific Officer to lead discovery research, translational research and early clinical development.  Dr. Houston was most recently Senior Vice President, Head of Specialty Discovery and R&D Site Evolution, Bristol-Myers Squibb (BMS). Dr. Houston has over 28 years of experience in the pharmaceutical industry and spent the last 18 years at BMS serving in multiple positions of increasing responsibility. Notably, he served on the executive team that drove decision-making on drugs such as daclatasvir (Daklinza), dapagliflozin (Forxiga), apixaban (Eliquis), ipilimumab (Yervoy) and nivolumab (Opdivo).